Hearing EF Hutton Initiated Coverage On Hoth Therapeutics With Buy Rating And $14 Price Target
Portfolio Pulse from Bill Haddad
EF Hutton initiated coverage on Hoth Therapeutics with a Buy rating and a $14 price target.
May 31, 2023 | 8:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hoth Therapeutics received a Buy rating and a $14 price target from EF Hutton.
The Buy rating and $14 price target from EF Hutton indicate a positive outlook for Hoth Therapeutics. This news is likely to attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100